VALARTH See Anthem Biosciences in the appOpen in app
ANTHEM · NSE · Biotechnology

Anthem Biosciences Ltd

What the numbers mean, from its filings and the exchange. Data as of 13 Oct 2026.
Mid Cap · AMFI list Jan-Jun 2026 · Vendor sector: Pharmaceuticals
dear low confidence No valuation within 120 days; P/E 84.1 vs peers 36.8 (19th of 23); P/B 11.6 vs peers 5.1 (23rd of 25).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Anthem Biosciences's share price today?

Anthem Biosciences last traded at ₹852.25 on the NSE, as of 13 Oct 2026, 9:45 am IST, down 3.5% on the day, up 12.6% over a year. Its 52-week range is ₹579 to ₹978. The live price is in the app.

₹852.25 −3.5% today
+12.6% over 1 year · NSE, as of 13 Oct 2026, 9:45 am IST
15 month-end closes, 31 Jul 2025 to 30 Sep 2026, adjusted for splits and bonuses
52-week range69% of the way up
Low ₹579High ₹978

What is Anthem Biosciences's market cap?

Anthem Biosciences's market capitalisation is about ₹49,774 crore: what it would cost to buy every share at today's price. That makes it the 97th largest mid cap company we cover.

₹49,774 Cr Mid Cap97th largest mid cap company
Mid Cap means the companies ranked 101 to 250 by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: ANTHEM
ISIN
INE0CZ201020
Cap bucket
Mid Cap, 97th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
Listed since
2025
Futures and options
Not traded

Is Anthem Biosciences overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 84.1 vs peers 36.8 (19th of 23); P/B 11.6 vs peers 5.1 (23rd of 25).

Valuation

Latest price and trailing 12 months
P/E 84.13
vs peers 36.8 · 19th of 23
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 11.57
vs peers 5.1 · 23rd of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹49,774 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.3%
vs peers 0.3% · 10th of 19
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) Not available
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 5.23
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
2 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; P/E vs own history: 0 of 36 months of P/E history

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Anthem Biosciences a quality business?

Quality score 64.7, 6th of 24 in its peer set; WATCH on 28 of 30 flags judged.

Quality and risk

Data as of 13 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 64.7
vs peers 53.3 · 6th of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
28 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 23.7%
vs peers 15.2% · 5th of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 31.0%
vs peers 17.9% · 4th of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 26.6%
vs peers 13.8% · 1st of 24
Profit after everything, as a share of revenue. Learn more →
EPS ₹10.54
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Anthem Biosciences made money for shareholders?

Yes: +12.6% over one year.

Shareholder returns

1-year return +12.6%
Price only
What the share price did over the last 12 months. Learn more →
5-year return Not available
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Not available
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−0.8%
1M
−6.3%
3M
+18.2%
6M
+21.0%
1Y
+12.6%
3Y
—
5Y
—
— not available

Does Anthem Biosciences pay a dividend?

Yes. Anthem Biosciences's dividend yield is 0.30% at the latest price; the last payout was ₹2.00 a share, ex-dividend 25 Jun 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.30%
The past 12 months' dividends as a share of today's price.
25 Jun 2026 · Final₹2.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Anthem Biosciences growing?

Revenue 3 years 24.0% a year; profit 3 years 15.4% a year; revenue 5 years 11.0% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 24.0% a year
vs peers 13.6% · 4th of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 15.4% a year
vs peers 20.9% · 14th of 21
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 11.0% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 7.3% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 16.1% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 16.4% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history Not available
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Anthem Biosciences do last quarter?

Anthem Biosciences reported revenue of ₹418 Cr, up 15.2% on a year earlier and a net profit of ₹120 Cr, up 31.1% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹418 Cr
+15.2% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹120 Cr
+31.1% on a year earlier
What was left for shareholders after every cost and tax.

How does Anthem Biosciences compare with its peers?

Compared with 24 Pharmaceuticals & Biotechnology (the industry, as the basic industry was too small); 19th of 23 on P/E; 6th of 24 on quality score.

Compared with 24 Pharmaceuticals & Biotechnology (the industry, as the basic industry was too small)

24 companies

Anthem Biosciences against its peers

Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Anthem Biosciences Ltd₹49,774 Cr84.111.623.7%31.0%+12.6%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+13.9%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+136.7%
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.1%
Dr Reddys Laboratories Ltd₹1.0 L Cr30.93.310.7%12.6%−2.6%
Mankind Pharma Ltd₹99,131 Cr47.95.013.3%13.1%−1.7%
Aurobindo Pharma Ltd₹98,211 Cr26.43.311.2%12.9%+50.1%
Lupin Ltd₹88,486 Cr15.83.523.4%27.5%−1.9%
Glenmark Pharmaceuticals Ltd₹64,432 Cr36.02.53.9%6.3%+19.6%
Alkem Laboratories Ltd₹62,234 Cr29.34.517.3%18.8%−5.2%
Biocon Ltd₹56,444 Cr102.82.20.9%1.6%−0.9%
Peer median—36.85.115.2%17.9%+33.8%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Anthem Biosciences?

Anthem Biosciences is held by promoters 71.4%, foreign institutions 2.6%, domestic institutions 13.5%.

Shareholding pattern

Latest filing, percent of shares
Promoters71.4%
The founders and controlling group.
Foreign institutions2.6%
Overseas funds investing through the FPI route.
Domestic institutions13.5%
Indian insurers, banks, pension and mutual funds together.
Mutual funds11.2%
Indian mutual fund schemes; part of domestic institutions.
Retail and others1.8%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Anthem Biosciences?

8 analysts cover Anthem Biosciences, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

8 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Anthem Biosciences do and what is it sensitive to?

Anthem reports two revenue lines, CRDMO and Specialty Ingredients, and says it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Sensitive to: forex gain within other operating income.

Business-model card

FY2026 · 25 verified
2Revenue
2Channels
0Regulators
6Reg. dependencies
3Sensitivities
2Costs
2Geographies

Anthem reports two revenue lines, CRDMO and Specialty Ingredients, and says it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Revenue from these lines is reported with EBITDA that includes forex gains and RoDTEP incentives within other operating income.

Revenue by segment

Q3FY26 (three months ended December 31, 2025), consolidated, from the quarterly Consolidated P&L table in excerpt 2; no full-year FY26 segment split is in the excerpts
CRDMO78.8%
Specialty Ingredients21.2%

Revenue engine

2 verified
CRDMO revenue line (83.2%)
Largest reported revenue line. Interpretation: the excerpts give the segment's revenue but do not explain how it earns beyond the customer description in the business summary.
Specialty Ingredients revenue line (16.8%)
Second reported revenue line. Interpretation: the excerpts show it declining in Q2 FY26 versus Q2 FY25 (₹781 Mn vs ₹899 Mn) and rising in 9MFY26 (₹2,535 Mn vs ₹2,475 Mn).

Customers & channels

2 verified
Innovator-focused emerging biotech and large pharmaceutical companies
Named customer groups. Interpretation: revenue depends on sales to these two customer types, and the excerpts do not give a share of revenue for either group.
One-stop service provider model
Company describes itself as a one-stop service provider. Interpretation: the excerpt describes the offer as end-to-end service to customers, with no channel or contract terms stated.

Regulatory dependencies

6 verified
Four Labour Codes notified November 21, 2025
Interpretation: a change in the wage definition and gratuity provisions raises employee cost. The company booked an incremental ₹254 Mn as an exceptional item in the quarter and nine months ended December 31, 2025, which reduces PBT after exceptional items.
Incremental labour-code impact of INR 254 Mn
Stated cost impact primarily from wage definition and gratuity provisions. Interpretation: the excerpt does not say whether this recurs; the company calls it non-recurring.
Pending Central and State Rules under the Labour Code
Interpretation: further rules could change the accounting effect, and the company says it will provide appropriate accounting effect as needed.
3 more statements
Draft Central Rules under the Labour Codes
Interpretation: draft rules were published but not final, so the eventual cost effect is not yet fixed.
RoDTEP incentives within other operating income
Interpretation: RoDTEP incentive is a government export-linked incentive that is counted in other operating income and therefore in EBITDA. Removing or reducing it would lower EBITDA.
Laws and regulations applying to pharmaceuticals
Interpretation: the company lists changes in pharmaceutical laws as a factor that could cause results to differ from expectations. The excerpts do not state the mechanism.

Sensitivities

3 verified
Forex gain within other operating income
Interpretation: when the forex gain (net) component rises, other operating income and EBITDA rise; a fall reduces them. The company reports Q2 FY26 other operating income at ₹303.40 Mn versus ₹38.25 Mn in Q2 FY25.
Higher prior-year quarter base
Company states quarterly revenue was influenced by a higher base in the same quarter last year. Interpretation: when the comparison base is high, year-on-year quarterly revenue growth falls.
Margin offsetting revenue shortfall
Company states margin improvement offset the revenue shortfall. Interpretation: EBITDA can rise even when revenue falls, as it did in Q3 FY26 (revenue down 15.0% YoY, EBITDA margin 41.8% vs 35.2%).

Cost inputs

2 verified
Cost of materials consumed and changes in inventories
Largest cost line in the P&L; the excerpts do not name suppliers. Interpretation: rising materials cost reduces EBITDA margin unless offset by price or mix.
Employee benefits expense
Interpretation: this line is affected by wage and gratuity rules, so the labour code change flows into this cost line. 9MFY26 expense is ₹2,102 Mn versus ₹2,007 Mn in 9MFY25.

Geographies

2 verified
Global customer base
Interpretation: the company says it serves customers globally; the excerpts give no regional revenue split.
India business and economic conditions
Listed as a risk factor for results. Interpretation: Indian economic and political conditions are named as factors that could affect results; the excerpts do not state the revenue share from India.
Each statement is checked word for word against the FY2026 annual report; the passages are in the app.

What changed recently?

Q4 FY2026 results filed (21 Sep 2026).

Change log

6 entries · newest first
  1. Results filedQ4 FY2026 results filed.
  2. Results filedQ1 FY2027 results filed.
  3. Corporate actionDividend - Rs 2 Per Share.
  4. Results filedQ3 FY2026 results filed.
  5. Results filedQ2 FY2026 results filed.
  6. Results filedQ1 FY2026 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored; P/E vs own history: 0 of 36 months of P/E history.
  • FlagsWATCH on 28 of 30 flags judged; 1 red; 2 could not be judged.
  • Data gapsPEG (vendor), Business quality, 5-year return, Wealth destroyer, P/E vs own history: not available yet.

What this page rests on

✓7 years of annual statements, through FY2026 (Mar-26)✓9 quarters of results✓15 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2026 · 25 verified

Questions people ask

What is Anthem Biosciences's share price today?

Anthem Biosciences last traded at ₹852.25 on the NSE, as of 13 Oct 2026, 9:45 am IST, down 3.5% on the day, up 12.6% over a year. Its 52-week range is ₹579 to ₹978. The live price is in the app.

What is Anthem Biosciences's market cap?

Anthem Biosciences's market capitalisation is about ₹49,774 crore: what it would cost to buy every share at today's price. That makes it the 97th largest mid cap company we cover.

Is Anthem Biosciences Ltd a large cap, mid cap or small cap?

Anthem Biosciences Ltd (ANTHEM) is a mid cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Anthem Biosciences Ltd's P/E ratio?

84.13, vs peers 36.8 · 19th of 23. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Anthem Biosciences Ltd overvalued?

Dear, with low confidence: no valuation within 120 days; P/E 84.1 vs peers 36.8 (19th of 23); P/B 11.6 vs peers 5.1 (23rd of 25).

How does Anthem Biosciences Ltd make money?

Anthem reports two revenue lines, CRDMO and Specialty Ingredients, and says it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Revenue from these lines is reported with EBITDA that includes forex gains and RoDTEP incentives within other operating income.

Who are Anthem Biosciences Ltd's peers?

Compared with 24 Pharmaceuticals & Biotechnology (the industry, as the basic industry was too small): Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd, Dr Reddys Laboratories Ltd, Mankind Pharma Ltd and 19 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Anthem Biosciences do last quarter?

Anthem Biosciences reported revenue of ₹418 Cr, up 15.2% on a year earlier and a net profit of ₹120 Cr, up 31.1% in the Jun 2026 quarter.

Who owns Anthem Biosciences?

Anthem Biosciences is held by promoters 71.4%, foreign institutions 2.6%, domestic institutions 13.5%.

Does Anthem Biosciences pay a dividend?

Yes. Anthem Biosciences's dividend yield is 0.30% at the latest price; the last payout was ₹2.00 a share, ex-dividend 25 Jun 2026.

What do analysts say about Anthem Biosciences?

8 analysts cover Anthem Biosciences, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

More mid cap companies

MRF LtdMRF · ₹51,916 CrLinde India LtdLINDEINDIA · ₹51,061 CrCoromandel International LtdCOROMANDEL · ₹49,858 CrSona BLW Precision Forgings LtdSONACOMS · ₹49,809 CrPB Fintech LtdPOLICYBZR · ₹48,450 CrHDB Financial Services LtdHDBFS · ₹48,331 CrIpca Laboratories LtdIPCALAB · ₹48,201 CrColgate-Palmolive (India) LtdCOLPAL · ₹48,060 Cr
All companies, by market cap →

Everything on Anthem Biosciences, and 6,621 other companies, with 212 filters and the full peer tables

See Anthem Biosciences in the app →See pricing